| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -3,355 |
| Depreciation and amortization expense | 18,343 |
| Stock-based compensation expense | 22,382 |
| Change in fair value of financial liabilities | 2,320 |
| Deferred tax expense (benefit) | 448 |
| Provision for excess and obsolete inventory | 152 |
| Legal reserves | -810 |
| Change in third party payor reserves | -8,746 |
| Other | 2,382 |
| Accounts receivable | 22,799 |
| Inventory | 72 |
| Accounts payable and accrued expenses | 5,185 |
| Other assets and liabilities | -1,827 |
| Net cash provided by (used in) operating activities | 36,369 |
| Acquisition of business, net of cash acquired | 33,195 |
| Purchases of property and equipment | 14,670 |
| Purchases of marketable securities | 36,535 |
| Proceeds from sales of marketable securities | 0 |
| Proceeds from maturities of marketable securities | 33,955 |
| Net cash used in investing activities | -50,445 |
| Proceeds from offerings, net of issuance costs | 25,568 |
| Proceeds from issuance of common stock pursuant to employee stock purchase plan | 1,262 |
| Exercise of stock options | 982 |
| Long-term debt principal payments | 906 |
| Finance lease principal payments | 2,074 |
| Net cash provided by financing activities | 24,832 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 10,756 |
| Cash and cash equivalents at beginning of period | 86,202 |
| Cash and cash equivalents at end of period | 96,958 |
GeneDx Holdings Corp. (WGSWW)
GeneDx Holdings Corp. (WGSWW)